- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
You are here
Trial Summary Table
| Trial Name | Phase | Start Date | Sponsors | Countries | Population | Candidate(s) | Status | Expected Completion Date |
|---|---|---|---|---|---|---|---|---|
| PrEPVacc / PV1 | IIb | Wednesday, January 1, 2020 | Sponsor: Imperial College London. Coordinating partners: P Kaleebu, E Ruzagira (MRC/UVRI & LSHTM, Uganda); J Weber/J Fox/C Kingsley (Imperial College, UK); S McCormack (UCL, UK); K Chinyenze (IAVI-Kenya); G Pantaleo/S Ding (CHUV/EVF, Switzerland) | Uganda, South Africa, United Republic of Tanzania, Mozambique | Men, Women | DNA , MVA, Protein | Ongoing | December 2024 |
| PrEPX | Demo Project | Tuesday, July 26, 2016 | Victorian Government, Alfred Health and the Victorian AIDS Council | Australia | Women, Men, MSM | Ongoing | March 2018 | |
| Project PrEPare (Adolescents 18-22) | Demo Project | Friday, November 30, 2012 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | United States of America | MSM | TDF/FTC (Truvada) | Ongoing | November 2015 |
| PROUD (pilot trial) | IV | Wednesday, October 31, 2012 | Medical Research Council | United Kingdom | Men, MSM | TDF/FTC (Truvada) | Completed | October 2016 |
| PSI Private Sector PrEP Program | Open Label | Friday, November 11, 2016 | UNITAID; PSI | South Africa | Women | Planned | ||
| PURPOSE 2 | III | Monday, June 14, 2021 | Gilead Sciences | United States of America | Men, MSM, Transgender men, Transgender women | Lenacapavir , F/TDF | Ongoing | April 2027 |
| PURPOSE 3/ HPTN 102 | Open Label | Women | Lenacapavir , TDF/FTC (Truvada) | Planned | ||||
| Purpose 4/ HPTN 103 | Open Label | Injecting drug users | Lenacapavir | Planned | ||||
| Queensland PrEP Demonstration Project (QPrEP) | Demo Project | Tuesday, September 29, 2015 | Queensland Health/HIV Foundation Queensland | Australia | MSM | Ongoing | November 2016 | |
| Right to Care (DREAMS) | Demo Project | PEPFAR, BMGF, Nike Foundation | Planned |